A Randomized, Open-label, Single Dose, 3-Period, 6-Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Apraglutide Versus the Reference Formulation Following Subcutaneous Administrations.
Phase 1
- Conditions
- HealthyMedDRA version: 20.1Level: PTClassification code: 10049416Term: Short-bowel syndrome Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2023-504430-22-00
- Lead Sponsor
- VectivBio AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method